Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project

Sean Patrick Bliven, Xiaoyan Wang, Morgan Lael, Anosheh Afghah, Mayur Narkhede

Blood (2025) 146 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2025-1830

Published: 2025

Journal Articles

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

Basem William, Madiha Iqbal, Natalie Galanina, Sarah Tomassetti, Cassandra Gillespie, Darryl Nousome, Antony Tin, Sharlene Velichko, Heather Youngberg, Catherine Bridges, Charuta Palsuledesai, Shruti Sharma, Angel Rodriguez, Minetta Liu, Mayur Narkhede

Blood (2025) 146 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2025-4353

Published: 2025

Journal Articles

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Lauren Shea, Lauren Hughey, Shantyle Kelly, Helen Obaro, Mayur Narkhede, Aditi Saha, Gaurav Goyal, Staci Shea, Heather Dillon, Paige Batson, Craig Elmets, Amitkumar Mehta

Blood (2025) 146 (Supplement 1): 7164.

https://doi.org/10.1182/blood-2025-7164

Published: 2025

Journal Articles

Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome

Sean Patrick Bliven, Lauren Shea, Aditi Saha, Smith Giri, Susan Bal, Antonio Di Stasi, Amitkumar Mehta, Mayur Narkhede

Blood (2025) 146 (Supplement 1): 5919.

https://doi.org/10.1182/blood-2025-5919

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Geoffrey P. Shouse, Kristie A. Blum, Julie E. Haydu, Jeremy S. Abramson, Mayur Narkhede, Andrew Ip, Jennifer S. Michaelson, Patrick A. Baeuerle, Kristan Meetze, Irina Shapiro, Todd Shearer, Judith Inumerable, Jeff Jones, Farrukh T. Awan

Blood (2023) 142 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2023-181239

Published: 2023

Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott

Blood (2023) 142 (Supplement 1): 68.

https://doi.org/10.1182/blood-2023-187113

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Smith Giri, Smith Giri, Clare Ubersax, Abigail Tucker, Susan Bal, Kelly Godby, Luciano Costa, Smita Bhatia, Grant Williams, Gayathri Ravi, Mayur Narkhede, Donna Murdaugh

Blood (2023) 142 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2023-189872

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Thrombocytopenia As a Risk Factor for Developing Febrile Neutropenia in Patients with DLBCL Receiving R-CHOP Chemotherapy

Ryan Edward Bailey, Sean Patrick Bliven, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 12122–12124.

https://doi.org/10.1182/blood-2022-163693

Published: 2022

Journal Articles

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Muthu Veeraputhiran, Amitkumar Mehta, Alvaro J. Alencar, Dipenkumar Modi, Timothy J. Voorhees, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 12089–12091.

https://doi.org/10.1182/blood-2022-158595

Published: 2022

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

Allison Winter, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 8054–8055.

https://doi.org/10.1182/blood-2022-162556

Published: 2022

Journal Articles

Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens

Star Ye, Christian Harmon, Nadia Anabtawi, Clare Ubersax, Abigail Tucker, Gaurav Goyal, Lauren Shea, Mayur Narkhede, Amitkumar Mehta, Purnima Singh, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 3779–3780.

https://doi.org/10.1182/blood-2022-163653

Published: 2022

Journal Articles

Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma

Mayur Narkhede, Lauren Shea, Gaurav Goyal, Amitkumar Mehta

Blood (2022) 140 (Supplement 1): 9358–9360.

https://doi.org/10.1182/blood-2022-164670

Published: 2022

Journal Articles

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Mayur Narkhede, Sarah Tomassetti, Madiha Iqbal, Katie LaBarbera, Hayley Widden, Ryan Benrud, Richa Rathore, Ekaterina Kalashnikova, Allyson Koyen Malashevich, Minetta Liu, Alexey Aleshin

Blood (2022) 140 (Supplement 1): 11884–11886.

https://doi.org/10.1182/blood-2022-169656

Published: 2022

Journal Articles

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Mayur Narkhede, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Allison Winter

Blood (2022) 140 (Supplement 1): 10798–10800.

https://doi.org/10.1182/blood-2022-162603

Published: 2022

Journal Articles

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goyal

Blood (2022) 140 (Supplement 1): 1076–1078.

https://doi.org/10.1182/blood-2022-169930

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J.M. Ferreri, Kate Cwynarski, Pamela McKay

Blood (2022) 139 (16): 2499–2511.

https://doi.org/10.1182/blood.2021014506

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Thrombocytopenia As a Risk Factor for Developing Febrile Neutropenia in Patients with DLBCL Receiving R-CHOP Chemotherapy

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens

Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only